Analyst Price Targets — VRTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 10, 2026 12:50 pm | — | Morgan Stanley | $612.00 | $436.89 | TheFly | Vertex Pharmaceuticals price target raised to $612 from $596 at Morgan Stanley |
| March 10, 2026 1:51 pm | Joon Lee | Truist Financial | $525.00 | $499.14 | StreetInsider | Vertex (VRTX) PT Raised to $525 at Truist Securities |
| March 10, 2026 9:37 am | Akash Tewari | Jefferies | $580.00 | $496.50 | StreetInsider | Jefferies Starts Vertex (VRTX) at Buy |
| March 2, 2026 2:28 pm | Evan David Seigerman | BMO Capital | $600.00 | $487.57 | StreetInsider | Vertex (VRTX) PT Raised to $600 at BMO Capital |
| February 17, 2026 12:01 pm | — | Canaccord Genuity | $441.00 | $491.47 | TheFly | Vertex Pharmaceuticals price target raised to $441 from $411 at Canaccord |
| February 17, 2026 11:35 am | Eliana Merle | Barclays | $607.00 | $491.47 | TheFly | Vertex Pharmaceuticals price target raised to $607 from $606 at Barclays |
| February 17, 2026 11:14 am | Andrew Fein | H.C. Wainwright | $591.00 | $491.47 | TheFly | Vertex Pharmaceuticals price target raised to $591 from $518 at H.C. Wainwright |
| February 13, 2026 4:08 pm | Terence Flynn | Morgan Stanley | $570.00 | $497.42 | TheFly | Vertex Pharmaceuticals price target raised to $570 from $564 at Morgan Stanley |
| February 13, 2026 3:28 pm | Louise Chen | Scotiabank | $558.00 | $493.98 | TheFly | Vertex Pharmaceuticals price target raised to $558 from $495 at Scotiabank |
| February 13, 2026 2:28 pm | — | RBC Capital | $541.00 | $496.02 | TheFly | Vertex Pharmaceuticals price target lowered to $541 from $546 at RBC Capital |
Latest News for VRTX
Merit Financial Group LLC lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 47.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,967 shares of the pharmaceutical company's stock after acquiring an additional 2,880 shares during the quarter. Merit
Davidson Investment Advisors boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 2.9% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 64,227 shares of the pharmaceutical company's stock after purchasing an additional 1,806 shares during the period. Vertex Pharmaceuticals comprises 1.2% of Davidson
Vertex Pharmaceuticals has shown steady financial growth. Mirum Pharmaceuticals is getting closer to being profitable.
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $441.2, representing a +1.27% change from its previous close.
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $435.65, indicating a -1.37% shift from the previous trading day.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.